Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coupang Inc (CPNG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Coupang IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Coupang Inc vs Inovio Pharmaceuticals Inc — how do they compare? Coupang Inc trades at $17.39 (market cap $32.17B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $95.85M). The key difference: Coupang Inc is far larger — about 335.6× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CPNGINO
Market Cap
$32.17B$95.85M
Sector
Consumer CyclicalHealth
52-Week High
$33.53$2.87
52-Week Low
$15.12$1.05
Enterprise Value
$31.26B$66.86M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coupang Inc

CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.

Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.

Inovio Pharmaceuticals Inc

INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.

The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.

Returns comparison

Trailing returns across standard periods

About Coupang Inc

Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.

Read more on CPNG

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO